Insider Trading Highlights at Janux Therapeutics Recent insider trading activity at Janux Therapeutics reveals significant movements, including a $300,000 stock sale by CEO David Alan Campbell and a $140,994 sale by insider Andrew Hollman Meyer. While these transactions indicate reduced insider holdings, institutional investors have remained active, with notable buy-ins bolstering confidence in the company.34